Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Mexico: These 39 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Mexico: These 39 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can ZTALMY (ganaxolone) generic drug versions launch in Mexico?

Generic name: ganaxolone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: Mexico Patent 2,008,006,888
Patent Title: FORMULAS Y METODOS PARA LA MANUFACTURA Y USO DE LA GANAXOLONA. (GANAXOLONE FORMULATIONS AND METHODS FOR THE MAKING AND USE THEREOF.)

ZTALMY is a drug marketed by Immedica Pharma. There are eleven patents protecting this drug. There has been litigation on patents covering ZTALMY

See drug price trends for ZTALMY.

The generic ingredient in ZTALMY is ganaxolone. Additional details are available on the ganaxolone profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch in Mexico?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: Mexico Patent 2,009,005,909
Patent Title: SAL FUMARATO DE (ALFA S, BETA R)-6-BROMO-ALFA-[2-(DIMETILAMINO)ETI L]-2-METOXI-ALFA-1-NAFTALENIL-BETA-FENIL-3-QUINOLINAETANOL. (FUMARATE SALT OF (ALPHA S, BETA R)-6-BROMO-ALPHA-[2-(DIMETHYLAMIN O)ETHYL]-2-METHOXY-ALPHA-1-NAPHTHALENYL-BETA-PHENYL-3-QUINOLINEE THANOL.)

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Mexico?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Mexico Patent 2,009,006,081

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Mexico?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Mexico Patent 2,010,002,336

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can PICATO (ingenol mebutate) generic drug versions launch in Mexico?

Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: Mexico Patent 2,008,007,685
Patent Title: COMPOSICIONES TERAPEUTICAS. (THERAPEUTIC COMPOSITIONS COMPRISING INGENOL-3-ANGELATE.)

Drug Price Trends for PICATO
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Mexico?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Mexico Patent 2,008,008,152
Patent Title: COMPUESTOS HETEROCICLICOS BICICLICOS. (BICYCLIC HETEROARYL COMPOUNDS.)

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Mexico?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Mexico Patent 343,042
Patent Title: COMPUESTOS HETEROARILICOS BICICLICOS. (BICYCLIC HETEROARYL COMPOUNDS.)

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can EPSOLAY (benzoyl peroxide) generic drug versions launch in Mexico?

Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Mexico Patent 2,009,008,256
Patent Title: METODO PARA PREPARAR PARTICULAS QUE COMPRENDEN RECUBRIMIENTO DE OXIDO DE METAL Y PARTICULAS CON RECUBRIMIENTO DE OXIDO DE METAL. (METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING.)

Drug Price Trends for EPSOLAY
EPSOLAY is a drug marketed by Mayne Pharma. There are fourteen patents protecting this drug. There has been litigation on patents covering EPSOLAY

See drug price trends for EPSOLAY.

The generic ingredient in EPSOLAY is benzoyl peroxide. Additional details are available on the benzoyl peroxide profile page.

When can EPSOLAY (benzoyl peroxide) generic drug versions launch in Mexico?

Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Mexico Patent 352,876
Patent Title: METODO PARA PREPARAR PARTICULAS QUE COMPRENDEN RECUBRIMIENTO DE OXIDO DE METAL Y PARTICULAS CON RECUBRIMIENTO DE OXIDO DE METAL. (METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING.)

Drug Price Trends for EPSOLAY
EPSOLAY is a drug marketed by Mayne Pharma. There are fourteen patents protecting this drug. There has been litigation on patents covering EPSOLAY

See drug price trends for EPSOLAY.

The generic ingredient in EPSOLAY is benzoyl peroxide. Additional details are available on the benzoyl peroxide profile page.

When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Mexico?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Mexico Patent 2,009,008,828
Patent Title: COMPOSICIONES DE ENZIMAS DIGESTIVAS ESTABLES. (STABLE DIGESTIVE ENZYME COMPOSITIONS.)

PANCREAZE is a drug marketed by

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Mexico?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Mexico Patent 2,009,008,828
Patent Title: COMPOSICIONES DE ENZIMAS DIGESTIVAS ESTABLES. (STABLE DIGESTIVE ENZYME COMPOSITIONS.)

ZENPEP is a drug marketed by

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can VARUBI (rolapitant hydrochloride) generic drug versions launch in Mexico?

Generic name: rolapitant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 22, 2027
Generic Entry Controlled by: Mexico Patent 2,009,010,210
Patent Title: FORMULACIONES DE COMPRIMIDOS QUE CONTIENEN SALES DE 8-[{1-(3,5-BIS-(TRIFLUOROMETIL)FENIL)-ETOXI}-METIL]-8-FENIL-1,7-D IAZA-SPIRO[4.5]DECAN-2-ONA Y COMPRIMIDOS ELABORADOS A PARTIR DE ESTAS. (TABLET FORMULATIONS CONTAINING 8-[{1-(3,5-BIS-(TRIFLUOROMETHYL)PH ENYL)-ETHOXY}-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE SALTS AND TABLETS MADE THEREFROM.)

VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.

The generic ingredient in VARUBI is rolapitant hydrochloride. Additional details are available on the rolapitant hydrochloride profile page.

When can AMYVID (florbetapir f-18) generic drug versions launch in Mexico?

Generic name: florbetapir f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 26, 2027
Generic Entry Controlled by: Mexico Patent 2,008,012,527

AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug. There has been litigation on patents covering AMYVID

The generic ingredient in AMYVID is florbetapir f-18. Additional details are available on the florbetapir f-18 profile page.

When can EDARBI (azilsartan kamedoxomil) generic drug versions launch in Mexico?

Generic name: azilsartan kamedoxomil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 28, 2027
Generic Entry Controlled by: Mexico Patent 2,009,010,167
Patent Title: COMPOSICION FARMACEUTICA SOLIDA QUE COMPRENDE UN DERIVADO DE BENCIMIDAZOL-7-CARBOXILATO Y UN AGENTE PARA EL CONTROL DEL PH. (SOLID PHARMACEUTICAL COMPOSITION COMPRISING A BENZIMIDAZOLE-7-CARBOXYLATE DERIVATIVE AND A PH CONTROL AGENT.)

Drug Price Trends for EDARBI
EDARBI is a drug marketed by Azurity. There is one patent protecting this drug. There has been litigation on patents covering EDARBI

See drug price trends for EDARBI.

The generic ingredient in EDARBI is azilsartan kamedoxomil. Additional details are available on the azilsartan kamedoxomil profile page.

When can INLYTA (axitinib) generic drug versions launch in Mexico?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: Mexico Patent 2,009,010,761

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Mexico?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Mexico Patent 2,008,012,945
Patent Title: MODULADORES DE TRANSPORTADORES DE CARTUCHO DE UNION A ADENOSINA-TRIFOSFATO CELULAR (ATP). (MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS.)

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can QVAR REDIHALER (beclomethasone dipropionate) generic drug versions launch in Mexico?

Generic name: beclomethasone dipropionate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 11, 2027
Generic Entry Controlled by: Mexico Patent 2,009,010,600

Drug Price Trends for QVAR REDIHALER
QVAR REDIHALER is a drug marketed by Norton Waterford. There are seventeen patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering QVAR REDIHALER

See drug price trends for QVAR REDIHALER.

The generic ingredient in QVAR REDIHALER is beclomethasone dipropionate. Additional details are available on the beclomethasone dipropionate profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Mexico?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Mexico Patent 2,009,011,881

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Mexico?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2027
Generic Entry Controlled by: Mexico Patent 2,008,014,289
Patent Title: COMPUESTOS HETEROARILICOS ACETILENICOS. (ACETYLENIC HETEROARYL COMPOUNDS.)

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Mexico?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2027
Generic Entry Controlled by: Mexico Patent 2,008,014,290
Patent Title: COMPUESTOS HETEROARILICOS MONOCICLICOS. (MONOCYCLIC HETEROARYL COMPOUNDS.)

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in Mexico?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: Mexico Patent 2,009,012,182

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in Mexico?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Mexico Patent 2,009,012,536
Patent Title: UNA COMPOSICION DE LIBERACION PROLONGADA QUE COMPRENDE UN DERIVADO DE SOMATOSTATINA EN MICROPARTICULAS. (AN EXTENDED-RELEASE COMPOSITION COMPRISING A SOMATOSTATIN DERIVATIVE IN MICROPARTICLES.)

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Mexico?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Mexico Patent 2,009,012,856

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Mexico?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Mexico Patent 2,009,012,856

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Mexico?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Mexico Patent 2,009,013,402

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can CARDAMYST (etripamil) generic drug versions launch in Mexico?

Generic name: etripamil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 20, 2027
Generic Entry Controlled by: Mexico Patent 2,009,014,052
Patent Title: BLOQUEADORES DEL CANAL DE CALCIO DE FENILALQUILAMINA DE ACCION CORTA Y SUS USOS. (SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF.)

Drug Price Trends for CARDAMYST
CARDAMYST is a drug marketed by Milestone Pharms Usa. There are six patents protecting this drug. There has been litigation on patents covering CARDAMYST

See drug price trends for CARDAMYST.

The generic ingredient in CARDAMYST is etripamil. Additional details are available on the etripamil profile page.

When can CARDAMYST (etripamil) generic drug versions launch in Mexico?

Generic name: etripamil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 20, 2027
Generic Entry Controlled by: Mexico Patent 347,325
Patent Title: BLOQUEADORES DEL CANAL DE CALCIO DE FENILALQUILAMINA DE ACCION CORTA Y SUS USOS. (SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF.)

Drug Price Trends for CARDAMYST
CARDAMYST is a drug marketed by Milestone Pharms Usa. There are six patents protecting this drug. There has been litigation on patents covering CARDAMYST

See drug price trends for CARDAMYST.

The generic ingredient in CARDAMYST is etripamil. Additional details are available on the etripamil profile page.

When can BYDUREON (exenatide synthetic) generic drug versions launch in Mexico?

Generic name: exenatide synthetic
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Mexico Patent 2,008,015,377

Drug Price Trends for BYDUREON
BYDUREON is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug. There has been litigation on patents covering BYDUREON

See drug price trends for BYDUREON.

The generic ingredient in BYDUREON is exenatide synthetic. Additional details are available on the exenatide synthetic profile page.

When can BYDUREON (exenatide synthetic) generic drug versions launch in Mexico?

Generic name: exenatide synthetic
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Mexico Patent 367,155

Drug Price Trends for BYDUREON
BYDUREON is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug. There has been litigation on patents covering BYDUREON

See drug price trends for BYDUREON.

The generic ingredient in BYDUREON is exenatide synthetic. Additional details are available on the exenatide synthetic profile page.

When can FARXIGA (dapagliflozin) generic drug versions launch in Mexico?

Generic name: dapagliflozin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Mexico Patent 2,008,015,377

Drug Price Trends for FARXIGA
FARXIGA is a drug marketed by Astrazeneca Ab. There are seventeen patents protecting this drug and one Paragraph IV challenge. Fifteen tentatively approved generics are ready to enter the market. There has been litigation on patents covering FARXIGA

See drug price trends for FARXIGA.

The generic ingredient in FARXIGA is dapagliflozin. Additional details are available on the dapagliflozin profile page.

When can FARXIGA (dapagliflozin) generic drug versions launch in Mexico?

Generic name: dapagliflozin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Mexico Patent 367,155

Drug Price Trends for FARXIGA
FARXIGA is a drug marketed by Astrazeneca Ab. There are seventeen patents protecting this drug and one Paragraph IV challenge. Fifteen tentatively approved generics are ready to enter the market. There has been litigation on patents covering FARXIGA

See drug price trends for FARXIGA.

The generic ingredient in FARXIGA is dapagliflozin. Additional details are available on the dapagliflozin profile page.

When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch in Mexico?

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Mexico Patent 2,008,015,377

Drug Price Trends for QTERN
QTERN is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering QTERN

See drug price trends for QTERN.

The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.

When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch in Mexico?

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Mexico Patent 367,155

Drug Price Trends for QTERN
QTERN is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering QTERN

See drug price trends for QTERN.

The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch in Mexico?

Generic name: remimazolam besylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: Mexico Patent 2,009,000,404
Patent Title: SALES DE BENZODIAZEPINA DE ACCION CORTA Y SUS FORMAS POLIMORFICAS. (SHORT-ACTING BENZODIAZEPINE SALTS AND THEIR POLYMORPHIC FORMS.)

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. Additional details are available on the remimazolam besylate profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Mexico?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Mexico Patent 2,010,001,256
Patent Title: PROCESO ENZIMATICO PARA OBTENER 17 ALFA-MONOESTERES DE CORTEXOLONA Y/O SUS 9, 11-DEHIDRODERIVADOS. (ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA-MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11-DEHYDRODERIVATIVES.)

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Mexico?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Mexico Patent 2,019,003,639
Patent Title: PROCESO ENZIMATICO PARA OBTENER 17 ALFA-MONOESTERES DE CORTEXOLONA Y/O SUS 9,11-DEHIDRODERIVADOS. (ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA-MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11-DEHYDRODERIVATIVES.)

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Mexico?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Mexico Patent 363,238
Patent Title: PROCESO ENZIMATICO PARA OBTENER 17 ALFA-MONOESTERES DE CORTEXOLONA Y/O SUS 9,11-DEHIDRODERIVADOS. (ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA-MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11-DEHYDRODERIVATIVES.)

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Mexico?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Mexico Patent 363,701
Patent Title: PROCESO ENZIMATICO PARA OBTENER 17 ALFA-MONOESTERES DE CORTEXOLONA Y/O SUS 9,11-DEHIDRODERIVADOS. (ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA-MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11-DEHYDRODERIVATIVES.)

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Mexico?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Mexico Patent 371,802
Patent Title: PROCESO ENZIMATICO PARA OBTENER 17-ALFA-MONOESTERES DE CORTEXOLONA Y/O SUS 9,11-DEHIDRODERIVADOS. (ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA-MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11-DEHYDRODERIVATIVES)

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can INTRAROSA (prasterone) generic drug versions launch in Mexico?

Generic name: prasterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: Mexico Patent 2,010,001,627
Patent Title: COMPOSICIONES DE DHEA PARA EL TRATAMIENTO DE LA MENOPAUSIA. (DHEA COMPOSITIONS FOR TREATING MENOPAUSE.)

Drug Price Trends for INTRAROSA
INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. Additional details are available on the prasterone profile page.

When can BRILINTA (ticagrelor) generic drug versions launch in Mexico?

Generic name: ticagrelor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 20, 2027
Generic Entry Controlled by: Mexico Patent 2,009,001,853

Drug Price Trends for BRILINTA
BRILINTA is a drug marketed by Astrazeneca. There are two patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering BRILINTA

See drug price trends for BRILINTA.

The generic ingredient in BRILINTA is ticagrelor. Additional details are available on the ticagrelor profile page.

When can BRILINTA (ticagrelor) generic drug versions launch in Mexico?

Generic name: ticagrelor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 20, 2027
Generic Entry Controlled by: Mexico Patent 340,403

Drug Price Trends for BRILINTA
BRILINTA is a drug marketed by Astrazeneca. There are two patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering BRILINTA

See drug price trends for BRILINTA.

The generic ingredient in BRILINTA is ticagrelor. Additional details are available on the ticagrelor profile page.

When can VIZAMYL (flutemetamol f-18) generic drug versions launch in Mexico?

Generic name: flutemetamol f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 30, 2027
Generic Entry Controlled by: Mexico Patent 2,010,002,196
Patent Title: COMPOSICION RADIOFARMACEUTICA. (RADIOPHARMACEUTICAL COMPOSITION.)

VIZAMYL is a drug marketed by Ge Healthcare. There is one patent protecting this drug.

See drug price trends for VIZAMYL.

The generic ingredient in VIZAMYL is flutemetamol f-18. Additional details are available on the flutemetamol f-18 profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Mexico?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Mexico Patent 2,010,005,346
Patent Title: COMPOSICIONES FARMACEUTICAS. (PHARMACEUTICAL COMPOSITIONS.)

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can ZEMDRI (plazomicin sulfate) generic drug versions launch in Mexico?

Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 21, 2027
Generic Entry Controlled by: Mexico Patent 2,010,005,632
Patent Title: ANALOGOS DE AMINOGLUCOSIDOS ANTIBACTERIANOS. (ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS.)

ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug. There has been litigation on patents covering ZEMDRI

See drug price trends for ZEMDRI.

The generic ingredient in ZEMDRI is plazomicin sulfate. Additional details are available on the plazomicin sulfate profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Mexico?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Mexico Patent 2,011,002,449

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in Mexico?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Mexico Patent 2,011,002,449

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch in Mexico?

Generic name: copanlisib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2027
Generic Entry Controlled by: Mexico Patent 2,009,006,001
Patent Title: DERIVADOS DE 2,3-DIHIDROIMIDAZO[1,2-C]QUINAZOLINA SUSTITUIDOS DE UTILIDAD EN EL TRATAMIENTO DE TRASTORNOS HIPERPROLIFERATIVOS Y ENFERMEDADES ASOCIADAS CON LA ANGIOGENESIS. (SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS.)

ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.

See drug price trends for ALIQOPA.

The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in Mexico?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: Mexico Patent 367,154
Patent Title: FORMAS SOLIDAS DE ACIDO 3-(6-(1-(2,2-DIFLUOROBENZO[D] [1,3]DIOXOL-5-IL)CICLOPROPANCARBOXAMIDO)-3-METILPIRIDIN-2-IL)BENZ OICO. (SOLID FORMS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3] DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL) BENZOIC ACID.)

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in Mexico?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 11, 2027
Generic Entry Controlled by: Mexico Patent 2,009,006,195
Patent Title: COMPUESTOS BASADOS EN 4-FENIL-6-(2,2,2-TRIFLUORO-1-FENILETOXI)PIRI MIDINA Y METODOS DE SU USO. (4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE.)

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can RYTARY (carbidopa; levodopa) generic drug versions launch in Mexico?

Generic name: carbidopa; levodopa
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 28, 2027
Generic Entry Controlled by: Mexico Patent 2,010,007,207
Patent Title: FORMULACIONES DE LIBERACION CONTROLADA DE LEVODOPA Y USOS DE LAS MISMAS. (CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF.)

RYTARY is a drug marketed by Impax. There are eight patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering RYTARY

See drug price trends for RYTARY.

The generic ingredient in RYTARY is carbidopa; levodopa. Additional details are available on the carbidopa; levodopa profile page.

Mexico Branded and Generic Drug Markets: Regulatory Opportunities, Patent Risk and Market Access

Last updated: October 17, 2026

Mexico is Latin America’s second-largest pharmaceutical market and has a mixed structure of originator brands, branded generics, low-cost generics, over-the-counter products and public-sector procurement. The market offers scale, manufacturing capacity and growing demand for chronic-disease medicines. Its main constraints are regulatory delays at COFEPRIS, fragmented public procurement, price pressure, patent-linkage uncertainty and uneven enforcement of intellectual-property rights.

Mexico has no U.S.-style Paragraph IV certification system and no broad statutory data exclusivity regime for conventional pharmaceuticals. Generic entry depends on regulatory approval, bioequivalence, patent-linkage review and the outcome of any patent dispute before the Mexican Institute of Industrial Property, known as IMPI.

How large is the Mexican branded and generic drug market?

Mexico has a population of approximately 130 million and a pharmaceutical market that is commonly estimated in the low double-digit billions of U.S. dollars, depending on whether estimates include retail, hospital, government procurement and medical-device sales. Public data do not provide one consolidated market figure, while commercial estimates differ in scope and currency.

The market has four economically important channels:

Channel Main buyers Market characteristics
Private retail Pharmacies, pharmacy chains, physicians and consumers Strong demand for branded generics, self-medication and chronic-care products
Private hospital Hospitals, insurers and distributors Greater use of originator brands and specialty medicines
Public procurement IMSS, ISSSTE, IMSS-Bienestar, state systems and military institutions Large tenders, price competition and payment risk
OTC and self-care Consumers, pharmacies and supermarkets High brand recognition and extensive local competition

Branded generics account for a substantial portion of private-sector sales. Companies such as Genomma Lab, Farmacias Similares, Laboratorios Sanfer, Pisa, Liomont, Chinoin, Siegfried Rhein and multinational affiliates compete with international originators and contract manufacturers.

The Mexican market is commercially attractive because demand is supported by diabetes, obesity, cardiovascular disease, oncology, respiratory disease and an aging population. The same conditions create intense price competition in primary care and chronic therapies.

What is the difference between branded generics and unbranded generics in Mexico?

Mexico is predominantly a branded-generic market in the private channel. A branded generic uses an independent trade name after patent or regulatory barriers have ended, while an unbranded generic is sold primarily under the active ingredient’s name.

Under Mexican law, generic medicines must demonstrate therapeutic equivalence through the requirements established by COFEPRIS and NOM-177-SSA1-2013. Depending on the product, this may involve in-vitro testing, comparative dissolution, pharmacokinetic bioequivalence or other recognized equivalence evidence. Interchangeability is determined through authorized testing units and approved protocols, not solely through a manufacturer’s declaration.

Originator companies retain commercial advantages after loss of exclusivity through:

  • Physician familiarity with the original brand.
  • Hospital and insurer formulary positioning.
  • Patient loyalty.
  • Manufacturing quality and supply reliability.
  • Device, formulation or administration advantages.
  • Trademark protection.

Generic manufacturers compete through lower prices, pharmacy distribution, private-label arrangements and public tenders.

What is the FDA and COFEPRIS regulatory status of medicines in Mexico?

COFEPRIS is Mexico’s federal regulator for medicines, biologics, medical devices, health establishments and related products. A medicine generally requires a Mexican sanitary registration before commercial sale.

Which rules govern drug approval in Mexico?

Key regulatory instruments include:

Regulatory area Principal Mexican framework
Marketing authorization General Health Law and Health Supplies Regulation
Good manufacturing practices NOM-059-SSA1-2015
Bioequivalence and interchangeability NOM-177-SSA1-2013
Clinical research NOM-012-SSA3-2012
Pharmacovigilance NOM-220-SSA1-2016
Labeling NOM-072-SSA1-2012
Biotechnological products NOM-257-SSA1-2014
Controlled substances General Health Law and controlled-substance rules
Advertising General Health Law and advertising regulations

A Mexican registration is generally valid for five years and requires renewal. The applicant must provide quality, safety and efficacy information appropriate to the product category. Foreign manufacturers usually need a Mexican legal representative and must comply with applicable manufacturing, importation, pharmacovigilance and distribution requirements.

COFEPRIS has introduced reliance and equivalence mechanisms for certain products approved by recognized foreign regulators. These mechanisms can reduce duplication, but eligibility and processing depend on the product category, reference authority and current administrative criteria.

When does a drug lose exclusivity in Mexico?

Mexico generally provides a 20-year patent term from the filing date, subject to Mexican patent-law rules. Patent term restoration for regulatory delay is not generally available for pharmaceutical products.

Regulatory approval does not itself create a broad period of market exclusivity for conventional drugs. Mexico’s principal exclusivity mechanisms are:

  1. Patent protection.
  2. Regulatory protection for certain biologics and biotechnology products.
  3. Orphan-drug or special-category rules where applicable.
  4. Data protection arguments based on international obligations and administrative practice.
  5. Trademark, formulation, device and manufacturing rights.

The practical loss-of-exclusivity date is therefore determined by the relevant patent family, the active-ingredient patent, formulation and dosage-form claims, method-of-use claims, manufacturing patents and any litigation outcome.

How does Mexican patent linkage work?

Mexico uses a patent-linkage system associated with Article 167 bis of the Health Supplies Regulation and publication of patent information in the Official Gazette. IMPI publishes lists of patents considered relevant to pharmaceutical products, while COFEPRIS reviews the relationship between a proposed product and listed patents.

The system is narrower and less predictable than U.S. Orange Book practice. It does not provide an exact equivalent to the Orange Book’s standardized patent-and-exclusivity database. Patent listings have historically focused on active ingredients and certain pharmaceutical claims, with continuing litigation over the eligibility of formulation, use and process patents.

A generic applicant may seek approval while contesting the relevance, validity or scope of a listed patent. The dispute may involve:

  • Administrative nullity proceedings before IMPI.
  • Patent infringement proceedings.
  • Federal administrative litigation.
  • Constitutional amparo proceedings.
  • Judicial review of COFEPRIS or IMPI actions.

What patent protection covers drugs in Mexico?

The Mexican pharmaceutical patent estate typically includes several layers:

Patent category Commercial function Generic-entry risk
Active ingredient Protects the chemical or biological entity Highest risk if still in force
Composition or formulation Protects excipients, stability or release profile Material for extended-release and injectable products
Dosage form Protects tablets, capsules, devices or delivery systems Relevant where the generic uses the same presentation
Method of use Protects treatment of a disease or patient group Depends on claim scope and product labeling
Manufacturing process Protects synthesis, purification or production method May create supply-chain and freedom-to-operate issues
Polymorph or salt Protects a solid form or chemical variant Can delay entry if commercially necessary
Device or combination product Protects injector, inhaler, pen or delivery system Important for biologics and specialty medicines

Mexico’s patent examination and litigation environment makes claim-by-claim freedom-to-operate analysis necessary. A composition patent may not block every generic version, while a process patent may create risk even when the active ingredient is no longer protected.

Does Mexico have Paragraph IV challenges?

Mexico does not have the U.S. Hatch-Waxman Paragraph IV certification process. A Mexican generic applicant does not file a formal Paragraph IV notice that automatically triggers a statutory 30-month stay.

Patent challenges instead arise through separate administrative and judicial mechanisms. A generic company may:

  • Argue that no listed patent applies.
  • Seek removal or correction of a patent from the linkage list.
  • Challenge validity before IMPI.
  • Defend against an infringement claim.
  • Seek judicial review of a regulatory refusal.
  • Use a non-infringing formulation or manufacturing route.

The absence of a formal Paragraph IV pathway reduces procedural predictability. It also means that patent disputes can emerge before or after regulatory filing, during procurement, or after commercial launch.

What is the biosimilar risk in Mexico?

Mexico recognizes biotechnological products and biocomparable products under the General Health Law and NOM-257-SSA1-2014. Biosimilar applicants must provide a comparative development package addressing analytical similarity, quality, nonclinical evidence where necessary, and clinical or pharmacodynamic data appropriate to the product.

Biosimilar risk is highest for biologics with:

  • Large public-sector expenditure.
  • Multiple competing suppliers.
  • Expiring composition or use patents.
  • Established local manufacturing capability.
  • Procurement rules that favor therapeutic substitution or lowest cost.

Biosimilar approval does not automatically resolve patent risk. Patent protection may remain for formulations, dosing regimens, indications, manufacturing processes, devices and administration systems. A biosimilar can obtain regulatory approval while facing a separate patent dispute.

Mexico’s biosimilar market is constrained by development cost, reference-product access, analytical capacity, physician confidence and procurement uncertainty. The opportunity is strongest in insulin, oncology, immunology and other high-cost biologics where public institutions seek lower treatment costs.

What is the Orange Book status of drugs in Mexico?

Mexico does not maintain an Orange Book equivalent with the same standardized function as the U.S. Food and Drug Administration’s Approved Drug Products with Therapeutic Equivalence Evaluations.

The relevant information is distributed across:

  • IMPI’s patent-linkage publications.
  • Mexican patent databases.
  • COFEPRIS sanitary registrations.
  • Official Gazette notices.
  • Court and IMPI decisions.
  • Manufacturer disclosures and licensing agreements.

Companies assessing Mexican generic entry should create a product-specific patent table rather than rely on a single public database.

What regulatory opportunities exist in Mexico?

Local manufacturing and contract manufacturing

Mexico has established pharmaceutical manufacturing, packaging and distribution capabilities. Local production can improve tender eligibility, reduce import dependence and support government procurement. It can also create licensing opportunities for multinational companies seeking Spanish-language labeling, local pharmacovigilance and regional supply.

Public procurement

Government purchasing is a large but volatile opportunity. Procurement has shifted among centralized purchasing mechanisms, institutional tenders, consolidated contracting and arrangements involving Birmex and IMSS-Bienestar. Winning suppliers must manage technical compliance, price reductions, delivery schedules, inventory requirements and payment timing.

High-cost and specialty medicines

Oncology, immunology, rare disease, diabetes and hospital anti-infectives offer higher revenue per product than mature primary-care generics. Regulatory and reimbursement access is more complex, but fewer competitors may support stronger margins.

Regulatory reliance

Products approved by recognized reference authorities may benefit from reliance-based review or equivalence pathways. The commercial value depends on whether COFEPRIS accepts the specific product category, manufacturing site and supporting assessment.

Digital and pharmacy distribution

Private pharmacy chains and e-commerce are expanding product visibility and consumer access. The opportunity is strongest for OTC medicines, dermatology, nutritional products and chronic-care therapies, subject to advertising and prescription rules.

What regulatory challenges affect drug companies in Mexico?

COFEPRIS processing and backlog

COFEPRIS has faced application backlogs, variable review times and administrative delays. Delays affect launch sequencing, renewal, manufacturing-site changes, pharmacovigilance updates and import permits.

Public procurement volatility

Tender rules, institutional demand, payment timing and procurement centralization can change rapidly. A company that depends on one public buyer faces concentration risk.

Price pressure

Generic substitution and pharmacy competition compress prices. Public tenders may reward the lowest compliant offer, making manufacturing efficiency and supply reliability more important than brand positioning.

Patent-linkage uncertainty

Patent listing criteria and judicial interpretation can change. A listed patent may create a regulatory obstacle without establishing the same clear enforcement status found in the United States.

Local compliance burden

Companies must maintain Mexican pharmacovigilance systems, local representatives, Spanish labeling, establishment licenses, import documentation, good manufacturing compliance and advertising controls.

Counterfeit and informal distribution

The formal market competes with unauthorized products and informal channels. Companies must manage serialization, distributor controls, pharmacy audits and adverse-event reporting.

Which companies compete in Mexico’s branded and generic drug market?

The competitive field includes multinational originators, Mexican laboratories, multinational generic companies, pharmacy-owned brands and contract manufacturers.

Company type Examples of competitive position
Originator multinationals Innovative medicines, specialty products, hospital brands
Mexican laboratories Local distribution, branded generics and public tenders
Pharmacy-linked groups High-volume low-price generics and private retail
Generic multinationals Portfolio breadth, manufacturing scale and regulatory expertise
Contract manufacturers Local production, packaging and licensing support
Biologic specialists Biosimilar development and specialty hospital products

No single company controls all channels. Retail strength does not guarantee public-sector success, and tender performance does not guarantee physician preference in private practice.

What licensing and partnership models work in Mexico?

Common structures include:

  • Exclusive or semi-exclusive distribution.
  • Local marketing authorization holder arrangements.
  • Technology-transfer and contract-manufacturing agreements.
  • Co-promotion of specialty products.
  • Licensing of branded generics.
  • Biosimilar development partnerships.
  • Regional supply agreements.
  • Patent settlement agreements.

A licensing agreement should allocate responsibility for COFEPRIS filings, patent-linkage review, pharmacovigilance, recalls, price approvals where applicable, tenders, inventory, currency exposure and product liability.

Settlement agreements can resolve patent disputes, but their enforceability and commercial value depend on claim scope, launch conditions, regulatory approval and competition-law considerations. A U.S. settlement does not automatically determine Mexican market-entry rights.

What generic launch scenarios exist in Mexico?

Scenario Timing and risk
Patent-free launch Lowest legal risk; entry follows regulatory approval
Launch after active-ingredient expiry Depends on formulation, use and process patents
At-risk launch Possible before complete patent resolution; high injunction and damages risk
Non-infringing formulation May avoid a listed patent but require separate development
License-backed launch Lower litigation exposure but includes royalties and restrictions
Public-tender launch Requires supply capacity and procurement eligibility
Biosimilar launch Requires regulatory comparability and biologic patent review

The strongest entry strategy combines a complete patent landscape, a COFEPRIS submission plan, a freedom-to-operate opinion and a procurement forecast.

How strong is the Mexican pharmaceutical patent estate?

Patent strength is product-specific. Active-ingredient patents that have survived examination and litigation provide the strongest barrier. Secondary patents are more vulnerable to validity challenges, but they can still delay entry through administrative review and injunction proceedings.

A practical strength assessment should score:

  1. Remaining patent term.
  2. Claim coverage of the commercial product.
  3. Patent-family continuity.
  4. Validity history.
  5. Listing status in IMPI’s linkage publication.
  6. Availability of alternative formulations.
  7. Manufacturing-route alternatives.
  8. Probability of public-sector substitution.
  9. Litigation posture.
  10. Evidence of prior settlements or licenses.

Mexico is not a jurisdiction where patent expiration alone determines commercial entry. Regulatory timing, procurement access and supply capacity can materially affect launch economics.

What revenue exposure does Mexico create for pharmaceutical companies?

Revenue exposure is highest where a product depends on:

  • One public institution.
  • One local distributor.
  • One manufacturing site.
  • A high-value biologic or oncology indication.
  • A patent nearing expiry.
  • A single formulation or device.
  • Government tenders with aggressive price reductions.

Originators face post-expiry erosion from branded generics and pharmacy-owned products. Generic companies face margin pressure and payment risk. Biosimilar manufacturers face development costs and uncertainty over interchangeability, procurement substitution and patent enforcement.

Key Takeaways

  • Mexico is a large, mixed pharmaceutical market with strong branded-generic demand and significant public procurement.
  • COFEPRIS approval, five-year registration renewal and NOM-based quality requirements govern market access.
  • Mexico has no U.S.-style Paragraph IV system and no Orange Book equivalent.
  • Patent linkage operates through IMPI publications and COFEPRIS review, but its scope remains more uncertain than in the United States.
  • Conventional pharmaceutical products generally rely on a 20-year patent term without broad regulatory exclusivity.
  • Formulation, use, process, polymorph, device and manufacturing patents can delay entry after active-ingredient expiry.
  • Biosimilar opportunities are strongest in high-cost public-sector therapies, but regulatory and patent analysis must proceed separately.
  • Local manufacturing, reliance pathways, private pharmacy distribution and public procurement create the main commercial opportunities.
  • COFEPRIS delays, tender volatility, price compression, payment risk and patent uncertainty are the principal market barriers.
  • Product-specific freedom-to-operate analysis is essential before a Mexican generic, branded-generic or biosimilar launch.

FAQs About Mexico’s Pharmaceutical Market

Is a Mexican marketing authorization enough to launch a generic drug?

No. The product must also satisfy patent-linkage requirements, comply with labeling and pharmacovigilance rules, and avoid infringing enforceable patents.

Does Mexico grant pharmaceutical data exclusivity?

Mexico does not operate a broad, clearly codified data-exclusivity system equivalent to the United States. Protection may depend on product category, international obligations and administrative or judicial interpretation.

Can a generic launch in Mexico before all patents expire?

It may be possible where no relevant patent applies, the product uses a non-infringing route or the company has a license. An at-risk launch can trigger administrative or judicial proceedings.

Are biosimilars automatically interchangeable in Mexico?

No. Biosimilarity, approval, prescribing practice and substitution are separate regulatory and commercial questions.

How long does a Mexican drug registration last?

A sanitary registration is generally valid for five years and must be renewed with COFEPRIS.

References

  1. Comisión Federal para la Protección contra Riesgos Sanitarios. (2013). NOM-177-SSA1-2013: Requirements for testing and procedures to demonstrate interchangeability of medicines and requirements for authorized third parties. Government of Mexico.

  2. Comisión Federal para la Protección contra Riesgos Sanitarios. (2014). NOM-257-SSA1-2014: Biotechnological products. Government of Mexico.

  3. Comisión Federal para la Protección contra Riesgos Sanitarios. (2015). NOM-059-SSA1-2015: Good manufacturing practices for medicines. Government of Mexico.

  4. Comisión Federal para la Protección contra Riesgos Sanitarios. (2016). NOM-220-SSA1-2016: Installation and operation of pharmacovigilance. Government of Mexico.

  5. Gobierno de México. (2024). Ley General de Salud. Cámara de Diputados.

  6. Gobierno de México. (2024). Reglamento de Insumos para la Salud. Cámara de Diputados.

  7. Instituto Mexicano de la Propiedad Industrial. (2024). Gaceta de la propiedad industrial: Patentes vigentes susceptibles de ser empleadas en medicamentos. Government of Mexico.

  8. Organisation for Economic Co-operation and Development. (2022). OECD reviews of health systems: Mexico. OECD Publishing.

  9. World Bank. (2024). Population, total: Mexico. World Development Indicators.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.